Phase II study of single-agent nivolumab in patients with myelofibrosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II study of single-agent nivolumab in patients with myelofibrosis
Authors
Keywords
-
Journal
ANNALS OF HEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-05
DOI
10.1007/s00277-021-04618-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New Concepts of Treatment for Patients with Myelofibrosis
- (2019) Prithviraj Bose et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Nivolumab combined with ruxolitinib: antagonism or synergy?
- (2018) P E Debureaux et al. ANNALS OF ONCOLOGY
- How we treat myelofibrosis after failure of JAK inhibitors
- (2018) Animesh Pardanani et al. BLOOD
- Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis
- (2018) Stine Ulrik Mikkelsen et al. Cancer Medicine
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study
- (2018) Naval Daver et al. Cancer Discovery
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Immunotherapy based approaches in myelofibrosis
- (2017) Lucia Masarova et al. Expert Review of Hematology
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
- (2016) S Koschmieder et al. LEUKEMIA
- Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
- (2015) Roberto Bellucci et al. OncoImmunology
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
- (2013) Richard T Silver et al. Expert Review of Hematology
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
- (2010) R. A. Mesa et al. BLOOD
- Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now